FOR ADULTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA

LIVE PROGRESSION FREE

In 2 different trials, patients lived progression free longer when treated with sarclisa plus other therapies.

In a clinical trial, SARCLISA + Kyprolis and dexamethasone (Kd) helped patients live progression free for a median of ~42 months vs ~21 months with Kd alone In a clinical trial, SARCLISA + Kyprolis and dexamethasone (Kd) helped patients live progression free for a median of ~42 months vs ~21 months with Kd alone

Trial 1: At a median follow-up of 44 months, patients lived progression free for a median of 41.7 months with SARCLISA + Kyprolis (carfilzomib) and dexamethasone (Kd) vs 20.8 months with Kd alone. At the time of this analysis, 56% (101 of 179 patients) lived progression free with SARCLISA + Kd vs 45% (55 of 123 patients) treated with Kd alone. In an earlier analysis, at a median follow-up of 20.7 months, 74% (133 of 179 patients) lived progression free with SARCLISA + Kd vs 59% (73 of 123 patients) treated with Kd alone.

Trial 2: At a median follow-up of 11.6 months, patients lived progression free for a median of 11.53 months with SARCLISA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs 6.47 months with Pd alone. At the time of this analysis, 53% (81 of 154 patients) lived progression free with SARCLISA + Pd vs 42% (64 of 153 patients) treated with Pd alone.

A median is the middle number in a group of numbers ordered from smallest to largest.

Find out more about the ~42 months results from the Phase 3 trial.

See the results

sarclisa is a targeted
immunotherapy that works
together with your
immune system.

See how it works
CareASSIST Patient Support by Sanofi

CareASSIST helps eligible patients with access and support for sarclisa.

Find out more